Abstract:Background: Viral infections of the respiratory tract represent a major global health concern. Co-infection with bacteria may contribute to severe disease and increased mortality in patients. Nevertheless, viral-bacterial co infection patterns and their clinical outcomes have not been well characterized to date. This study aimed to evaluate the clinical features and outcomes of patients with viral-bacterial respiratory tract co-infections. Methods: We included 19,361 patients with respiratory infection due to respiratory viruses [influenza A and B, respiratory syncytial virus (RSV), parainfluenza] and/or bacteria in four tertiary hospitals in Hong Kong from 2013 to 2017 using a large territory-wide healthcare database. All microbiological tests were conducted within 48 h of hospital admission. Four etiological groups were included: (1) viral infection alone; (2) bacterial infection alone; (3) laboratory-confirmed viral-bacterial co-infection and (4) clinically suspected viral-bacterial co-infection who were tested positive for respiratory virus and negative for bacteria but had received at least four days of antibiotics. Clinical features and outcomes were recorded for laboratory-confirmed viral-bacterial co-infection patients compared to other three groups as control. The primary outcome was 30-day mortality. Secondary outcomes were intensive care unit (ICU) admission and length of hospital stay. Propensity score matching estimated by binary logistic regression was used to adjust for the potential bias that may affect the association between outcomes and covariates. Findings: Among 15,906 patients with respiratory viral infection, there were 8451 (53.1%) clinically suspected and 1,087 (6.8%) laboratory-confirmed viral-bacterial co-infection. Among all the bacterial species, Haemophilus influenzae (226/1,087, 20.8%), Pseudomonas aeruginosa (180/1087, 16.6%) and Streptococcus pneumoniae (123/ 1087, 11.3%) were the three most common bacterial pathogens in the laboratory-confirmed co-infection group. Respiratory viruses co-infected with non-pneumococcal streptococci or methicillin-resistant Staphylococcus aureus was associated with the highest death rate [9/30 (30%) and 13/48 (27.1%), respectively] in this cohort. Compared with other infection groups, patients with laboratory-confirmed co-infection had higher ICU admission rate (p < 0.001) and mortality rate at 30 days (p = 0.028), and these results persisted after adjustment for potential confounders using propensity score matching. Furthermore, patients with laboratory-confirmed co infection had significantly higher mortality compared to patients with bacterial infection alone. Interpretation: In our cohort, bacterial co-infection is common in hospitalized patients with viral respiratory tract infection and is associated with higher ICU admission rate and mortality. Therefore, active surveillance for bacterial co-infection and early antibiotic treatment may be required to improve outcomes in patients with respiratory viral infection. Funding: Commissioned Programmes for Influenza Research, Health and Medical Research Fund (HMRF), FHB (Ref. No.: INF-CUHK-2); National Natural Science Foundation of China (81873560); Shenzhen Science and Technology Programme, Shenzhen Science and Technology Innovation Commission (JCYJ20180307150626228); Health and Medical Research Fund (18170092). (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Risk factors, outcomes, and epidemiological and etiological study of hospitalized COVID-19 patients with bacterial co-infection and secondary infections

Secondary bacterial infections in critical ill patients of COVID-19

Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study

Clinical characteristics and risk factors for bacterial co-infections in COVID-19 patients: A retrospective study

Secondary Bacterial Infections in Critical Ill Patients with Coronavirus Disease 2019.

Secondary Infection in Severe and Critical COVID-19 Patients in China: a Multicenter Retrospective Study.

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Outcomes of Respiratory Viral-Bacterial Co-Infection in Adult Hospitalized Patients.

Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China

Risks and Features of Secondary Infections in Severe and Critical Ill COVID-19 Patients

Bacterial co-infection in COVID-19: a call to stay vigilant

Clinical features of omicron SARS-CoV-2 variants infection associated with co-infection and ICU-acquired infection in ICU patients

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Characterization of Microbial Co-infections in the Respiratory Tract of hospitalized COVID-19 patients

Mortality in hospitalized SARS-CoV-2 patients with contemporaneous bacterial and fungal infections

Impact of Coinfection with SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-Analysis

Bloodstream Coinfections and Antimicrobial Resistance in Hospitalized COVID-19 Patients: A Single-center Retrospective Study

Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

Co-infections in people with COVID-19: a systematic review and meta-analysis

Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression